Patients who stop taking injectable GLP-1 or GLP-1/GIP receptor agonists like semaglutide or tirzepatide face significant weight regain, but new data show that pursuing bariatric surgery, switching medications, or maintaining active treatment strategies can preserve metabolic gains, according to findings presented at ObesityWeek.
Weight Regain Risks and Strategies to Maintain Loss
- Stopping GLP-1 weight-loss drugs without a backup plan usually leads to rapid weight regain and a return of high blood pressure and blood sugar.
- Switching between semaglutide and tirzepatide, or moving to another obesity medication, helps patients hold onto most of their weight loss.
- Bariatric surgery yields the greatest two-year weight reduction among all tested post-discontinuation strategies, though very few patients choose this path.
Two-Year Outcomes Across Five Post-Discontinuation Strategies
Researchers at the Cleveland Clinic analyzed electronic health records from 20,486 patients in Ohio and Florida who were initially treated for obesity or type 2 diabetes with semaglutide or tirzepatide between January 2021 and December 2023, Medscape reported. The findings, published in eClinicalMedicine, evaluated outcomes across five distinct clinical pathways after patients completed at least three months of initial therapy.
The study tracked a patient cohort with a mean age of 56.7 years, a baseline body mass index (BMI) of 38 kg/m², and high prevalences of type 2 diabetes at 65.7% and hypertension at 68%. Per-protocol analyses revealed stark contrasts in weight maintenance two years after altering the initial regimen. Patients who discontinued all treatment entirely retained weight reduction from their baseline.
Conversely, patients who remained on their original medication maintained a 10.9% weight reduction. Most notably, patients who underwent metabolic bariatric surgery recorded the steepest drop, achieving a 28.2% weight reduction.
| Post-Discontinuation Strategy | Patient Cohort Representation | Two-Year Weight Reduction |
|---|---|---|
| Metabolic Bariatric Surgery | Lowest uptake (~1%) | 28.2% |
| Switching Semaglutide and Tirzepatide | Moderate | |
| Continuing Original Medication | High | 10.9% |
| Switching to Another Obesity Medication | Moderate | 8.2% |
| Discontinuing Treatment Entirely | High discontinuation rates (47%–65%) |
Drug Switching Affects Weight Loss and Blood Pressure
Cleveland Clinic Newsroom reported that patients who transitioned from semaglutide to tirzepatide lost more weight than those who stayed on semaglutide, showing a difference of 3.0 kg (6.6 lb). However, patients who started on tirzepatide achieved better outcomes by remaining on their original drug rather than switching to semaglutide, with a difference of 4.5 kg (10 lb). Similar patterns emerged for glycated hemoglobin (A1c) and systolic blood pressure.
“Roughly 1% of patients who discontinue semaglutide or tirzepatide undergo bariatric surgery within a year after discontinuation,” lead author Hamlet Gasoyan noted. Cost, insurance limitations, and side effects remain common reasons patients stop treatment.
“To our knowledge, this is the first study to compare weight change and cardiometabolic parameters across several obesity treatment strategies in patients who initially took injectable semaglutide or tirzepatide for obesity or type 2 diabetes,” Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, told Medscape Medical News.
“Our results could support patient–clinician discussions about alternative therapy options in patients who consider switching or stopping these medications,” Gasoyan said.
Maria Daniela Hurtado Andrade, MD, PhD, assistant professor at the Mayo Clinic Alix School of Medicine in Jacksonville, Florida, emphasized the value of personalized clinical counseling during the post-treatment phase. “The patient journey matters when we are talking and discussing treatment options,” she told Medscape Medical News.
Contraindications & When to Consult a Doctor
Patients considering stopping or switching their injectable incretin therapies must evaluate potential clinical risks with a qualified healthcare provider. Individuals with a history of severe gastrointestinal disease, pancreatitis, or specific endocrine tumors must avoid certain pharmacologic agents. Gastrointestinal side effects during the initial 90-day titration phase, including severe nausea, vomiting, or suspected gastroparesis, require immediate medical evaluation.
Patients who experienced emergency department visits or inpatient admissions for biliary disease, bowel obstruction, or severe pancreatitis during their first three months of treatment were 1.8 times more likely to discontinue their index medication. Abrupt cessation without a structured clinical exit plan frequently triggers rapid metabolic reversion, elevating systolic blood pressure and glycemic markers.
Future Directions in Personalized Obesity Care
The research team plans to utilize their electronic health record data to develop an interactive, evidence-based decision aid. This tool aims to assist clinicians and patients in evaluating individualized expected benefits and risks before modifying a weight management regimen. Prospective real-world studies are slated to validate these observational findings and refine long-term clinical guidelines.
“The encouraging news is that, for patients who need to stop their injectable GLP-1 medication, it does not mean that their obesity treatment journey has to end,” Dr. Gasoyan said.
References
- Gasoyan H, et al. Comparative effectiveness of alternative obesity treatment strategies after discontinuation of injectable semaglutide or tirzepatide. eClinicalMedicine. Published November 2026.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. The Lancet / PubMed.
- West S, et al. Weight loss and weight regain associated with long-term pharmacotherapy for obesity: A systematic review. The BMJ. January 2026.
